A key consideration for clinical trials will be selecting patients whose tumors are BCAT1-driven (e.g., by measuring BCAT1 expression or activity in the tumor) so that those most likely to benefit receive the treatment [104]. This evidence concerns the gene BCAT1 and neoplasm.